Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 3 | 12 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 2 | 8 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $93.33, along with a high estimate of $106.00 and a low estimate of $85.00. Observing a 2.71% increase, the current average has risen from the previous average price target of $90.87.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how financial experts perceive Medtronic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Shagun Singh | RBC Capital | Raises | Sector Perform | $98.00 | $92.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $104.00 | $100.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $92.00 | $85.00 |
| Richard Newitter | Truist Securities | Raises | Hold | $90.00 | $85.00 |
| Matt Miksic | Barclays | Raises | Overweight | $105.00 | $104.00 |
| Steven Lichtman | Oppenheimer | Raises | Perform | $94.00 | $92.00 |
| Matt O'Brien | Piper Sandler | Raises | Neutral | $90.00 | $85.00 |
| Shagun Singh | RBC Capital | Maintains | Sector Perform | $92.00 | $92.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $106.00 | $105.00 |
| David Rescott | Baird | Raises | Neutral | $90.00 | $82.00 |
| Rick Wise | Stifel | Raises | Hold | $87.00 | $85.00 |
| Danielle Antalffy | UBS | Raises | Neutral | $90.00 | $76.00 |
| Rick Wise | Stifel | Lowers | Hold | $85.00 | $100.00 |
| Shagun Singh | RBC Capital | Maintains | Sector Perform | $92.00 | $92.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $85.00 | $88.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Medtronic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Medtronic analyst ratings.
All You Need to Know About Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Understanding the Numbers: Medtronic's Finances
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Medtronic showcased positive performance, achieving a revenue growth rate of 2.77% as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin excels beyond industry benchmarks, reaching 13.16%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Medtronic's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Medtronic's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.16%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.58, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
